1. Home
  2. OLOX vs SILO Comparison

OLOX vs SILO Comparison

Compare OLOX & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Olenox Industries Inc. Common Stock

OLOX

Olenox Industries Inc. Common Stock

N/A

Current Price

$5.59

Market Cap

6.1M

ML Signal

N/A

Logo Silo Pharma Inc.

SILO

Silo Pharma Inc.

HOLD

Current Price

$0.41

Market Cap

7.2M

ML Signal

HOLD

Company Overview

Basic Information
Metric
OLOX
SILO
Founded
2007
2010
Country
United States
United States
Employees
N/A
N/A
Industry
RETAIL: Building Materials
Apparel
Sector
Consumer Discretionary
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
6.1M
7.2M
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
OLOX
SILO
Price
$5.59
$0.41
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
213.5K
1.4M
Earning Date
06-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.98
EPS
N/A
N/A
Revenue
N/A
$72,102.00
Revenue This Year
$1,628.82
$1.86
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.45
$0.22
52 Week High
$5.75
$1.01

Technical Indicators

Market Signals
Indicator
OLOX
SILO
Relative Strength Index (RSI) 89.97 47.27
Support Level $0.58 $0.40
Resistance Level N/A $0.42
Average True Range (ATR) 0.37 0.03
MACD 0.53 -0.01
Stochastic Oscillator 96.98 35.90

Price Performance

Historical Comparison
OLOX
SILO

About OLOX Olenox Industries Inc. Common Stock

Olenox Industries Inc is an industrial holding company focused on acquiring, operating, and scaling businesses that provide engineered solutions across industrial, energy, and infrastructure markets. Through its subsidiaries, it delivers high-quality modular and containerized systems designed for rapid deployment and long-term performance.

About SILO Silo Pharma Inc.

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.

Share on Social Networks: